Trade

with

Rexahn Pharmaceuticals Inc
(Amex: RNN)
AdChoices
0.7567
-0.0013
-0.17%
After Hours :
0.7400
-0.0167
-2.21%

Open

0.7700

Previous Close

0.7580

Volume (Avg)

520.91k (1.01M)

Day's Range

0.7016-0.7700

52Wk Range

0.3700-1.85

Market Cap.

134.88M

Dividend Rate ( Yield )

-

Beta

1.14

Shares Outstanding

178.25M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -9.50M

    • Market Cap.

    • 134.88M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.14

    • Forward P/E

    • -6.88

    • Price/Sales

    • -

    • Price/Book Value

    • 4.45

    • Price/Cash flow

    • -12.47

      • EBITDA

      • -7.94M

      • Return on Capital %

      • -76.58

      • Return on Equity %

      • -107.60

      • Return on Assets %

      • -76.58

      • Book Value/Share

      • 0.17

      • Shares Outstanding

      • 178.25M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 3.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.11

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 25.40

              • 2.92

              • Quick Ratio

              • 24.81

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.29

              • 2.21

              • Book Value/Share

              • 0.17

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -6.12

                • 217.39

                • P/E Ratio 5-Year High

                • -29.77

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.27

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 4.45

                • 8.61

                • Price/Cash Flow Ratio

                • -12.47

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -107.60

                    (-104.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -76.58

                    (-74.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -107.60

                    (-104.90)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -7.98M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -12.47
                  Ownership

                  Institutional Ownership

                  16.16%

                  Top 10 Institutions

                  20.18%

                  Mutual Fund Ownership

                  3.12%

                  Float

                  95.27%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,516,154

                  • 5.02

                  • 1.41

                  • Vanguard Extended Market Index Fund

                  •  

                    1,449,610

                  • 4.85

                  • 0.81

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    555,279

                  • 0.00

                  • 0.31

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    252,511

                  • 0.00

                  • 0.14

                  • Bridgeway Ultra Small Company Market

                  •  

                    180,000

                  • 0.00

                  • 0.10

                  • AQR Small Cap Momentum Fund

                  •  

                    140,800

                  • 0.00

                  • 0.08

                  • Vanguard Balanced Index Fund

                  •  

                    112,317

                  • 0.00

                  • 0.06

                  • Global Trend Equity OP

                  •  

                    100,000

                  • 0.00

                  • 0.06

                  • EB DL Non-SL Market Completion Fund

                  •  

                    86,626

                  • 166.53

                  • 0.05

                  • Master Extended Market Index Series

                  •  

                    36,171

                  • 0.00

                  • 0.02

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Teva Pharmaceutical Industries Ltd,

                  •  

                    7,520,685

                  • +38.32%

                  • 6.30

                  • Sabby Management LLC

                  •  

                    7,321,218

                  • -14.79%

                  • 4.99

                  • KT&G Corp

                  •  

                    6,390,922

                  • 0.00%

                  • 5.35

                  • Vanguard Group, Inc.

                  •  

                    3,574,300

                  • +0.56%

                  • 2.01

                  • Morgan Stanley & Co Inc

                  •  

                    1,235,989

                  • +246.60%

                  • 0.69

                  • Geode Capital Management, LLC

                  •  

                    714,939

                  • +40.89%

                  • 0.40

                  • Northern Trust Investments, N.A.

                  •  

                    235,335

                  • +18.09%

                  • 0.13

                  • AQR Capital Management LLC

                  •  

                    213,900

                  • -43.77%

                  • 0.12

                  • Bridgeway Capital Management, Inc

                  •  

                    180,000

                  • 0.00%

                  • 0.10

                  • Wells Fargo Advisors, LLC

                  •  

                    152,750

                  • +4.98%

                  • 0.09

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Rexahn Pharmaceuticals, Inc., was incorporated on May 13, 2005 with the merger of Corporate Road Show.Com Inc., a New York corporation (“CPRD”), and Rexahn, Corp, a Maryland corporation, immediately after giving effect to a 1 for 100...more reverse stock split and the reincorporation of CPRD as a Delaware corporation under the name “Rexahn Pharmaceuticals, Inc.”. The Company is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The Company currently has three clinical stage oncology candidates. The first candidate, Archexin, is an inhibitor of the protein kinase Akt. Akt plays critical roles in cancer cell proliferation, survival, angiogenesis, metastasis, and drug resistance. Another clini...morecal stage candidate is RX-3117, which is a small molecule, new chemical entity nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers, including colon, lung, and pancreatic cancer. Supinoxin, or RX-5902 is another clinical stage oncology candidate that is a first-in-class small molecule that inhibits the phosphorylation of p68 RNA helicase, a protein that plays a key role in cancer growth, progression, and metastasis. The Company’s drug candidates would be competing with products and therapies that either currently exist or are expected to be developed. Archexin would compete with other Akt inhibitors, such as MK-2206 and GSK-2141795, which is under development by Merck & Company, Inc. and Glaxo-SmithKline, respectively. It are not currently aware of known inhibitors of phosphorylated p68 that would compete with Supinoxin. The Company holds U.S. patents for Archexin, RX-3117, Supinoxin and RX-0047. It also holds multiple foreign patents for Archexin, RX-3117, Supinoxin and RX-0047. It is regulated by governmental authorities in the United States and in other countries.lessless

                  Key People

                  Peter D. Suzdak,PhD

                  CEO/Director

                  Dr. Chang Ho Ahn,PhD

                  Chairman of the Board/Chief Scientific Officer/Director

                  Tae Heum (Ted) Jeong

                  CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional

                  Charles Beever

                  Director

                  Dr. Kwang Soo Cheong,PhD

                  Director

                  • Rexahn Pharmaceuticals Inc

                  • 15245 Shady Grove Road

                  • Rockville, MD 20850

                  • USA.Map

                  • Phone: +1 240 268-5300

                  • Fax: +1 240 268-5310

                  • rexahn.com

                  Incorporated

                  2005

                  Employees

                  16

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: